DelphX Announces Grant of Stock Options
Rhea-AI Summary
DelphX Capital Markets (TSXV: DELX) (OTCQB: DPXCF), a company focused on developing structured products for the fixed income market, has announced a new stock option grant. The Board of Directors has approved 1,750,000 stock options for eligible participants under its stock option plan. These options come with a two-year maturity period and can be exercised at $0.20 per common share.
Positive
- Stock options grant provides incentive alignment between option holders and shareholders
Negative
- Potential dilution of 1,750,000 shares if all options are exercised
- Exercise price of $0.20 represents potential dilution value of $350,000
Toronto, Ontario--(Newsfile Corp. - December 31, 2024) - DelphX Capital Markets Inc. (TSXV: DELX) (OTCQB: DPXCF) ("DelphX"), a leader in the development of new classes of structured products for the fixed income market, announces that its Board of Directors has approved the grant of 1,750,000 stock options (the "Options") to eligible participants under its stock option plan (the "Plan"). The Options have a two-year maturity and are exercisable for common shares of DelphX at an exercise price of
About DelphX Capital Markets Inc.
DelphX is a technology and financial services company focused on developing and distributing the next generation of structured products. Through its special purpose vehicle Quantem LLC, the Company enables fixed income dealers to offer new private placement securities that provide mitigation of spread and capital charge losses when downgrades occur, while allowing for attractive returns. The new DelphX securities will enable dealers and their qualified institutional investors (QIBs) accounts to competitively structure, sell and make markets in:
- Collateralized put options (CPOs) that provide secured rating downgrade protection for underlying corporate bonds;
- Collateralized reference notes (CRNs) that enable investors to take on a capped rating downgrade exposure of an underlying security in exchange for attractive returns.
All CPOs and CRNs are fully collateralized and held in custody by BNY Mellon. CPOs and CRNs are proprietary products created and owned by DelphX Capital Markets.
For more information about DelphX, please visit www.delphx.com.
George Wentworth, General Manager
DelphX Capital Markets Inc.
george.wentworth@delphx.com
(718) 509-2160
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/235685
FAQ
How many stock options did DelphX (DPXCF) grant in December 2024?
What is the exercise price for DelphX's (DPXCF) December 2024 stock options?
What is the maturity period for DelphX's (DPXCF) December 2024 stock options?
What is the potential dilution value of DelphX's (DPXCF) December 2024 stock options?
